Sensorion Reports Positive Preliminary Results for SENS-501

Biotech company Sensorion has revealed promising data from its Phase 1/2 Audiogene clinical trial focusing on the gene therapy SENS-501. This treatment is intended for infants suffering from congenital deafness due to mutations in the OTOF gene. The first two patients tolerated the treatment well without major incidents, and encouraging behavioral improvements were observed.

Sensorion plans to hold an online meeting in early 2025 to discuss the results and consider next steps in development, including discussions with the FDA. The company plans to enroll its second cohort by mid-2025.

Géraldine Honnet, Medical Director, expressed her satisfaction with the progress of the trial, promising new standards for treating otoferlin deficiency. Professor Natalie Loundon highlighted the potential of this therapy to improve hearing and quality of life for affected children.